Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pulmonx (DE:4NI)
STUTTGART:4NI
Pulmonx (4NI) Stock Price & Analysis
0 Followers
4NI Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€6.90 - €13.60
Previous Close€6.9
Volume0.00
Average Volume (3M)110.00
Market Cap
€271.27M
Enterprise Value€200.33M
Total Cash (Recent Filing)$117.10M
Total Debt (Recent Filing)$41.42M
Price to Earnings (P/E)N/A
Beta-0.08
Next Earnings
May 01, 2024EPS Estimate
-€0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume110
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.92
Enterprise Value/Gross Profit3.95
Enterprise Value/Ebitda-4.68
Forecast
1Y Price Target
€15.78Price Target Upside128.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Pulmonx News
Bulls Say, Bears Say
Bulls Say
Earnings GrowthLUNG has delivered strong growth with 2023 sales growing 28% year over year.
Financial PerformanceGross margins expanded to 74.7%, showing improved profitability through efficiencies in production and pricing.
Market ExpectationsManagement's revenue guidance for 2024 is above consensus, suggesting confidence in the company's growth trajectory.
Bears Say
Financial ForecastLUNG does not expect material revenue in Japan until 2026 due to the post-approval study it is required to conduct.
Management StabilityManagement changes with the CFO leaving the company and the new CEO being in his first CEO role create uncertainty.
Stock ValuationThe price target for the company has been lowered, reflecting a more cautious outlook on its valuation.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.69% Other Institutional Investors
99.31% Public Companies and
Individual Investors
4NI FAQ
What was Pulmonx’s price range in the past 12 months?
Pulmonx lowest stock price was €6.90 and its highest was €13.60 in the past 12 months.
What is Pulmonx’s market cap?
Currently, no data Available
When is Pulmonx’s upcoming earnings report date?
Pulmonx’s upcoming earnings report date is May 01, 2024 which is in 7 days.
How were Pulmonx’s earnings last quarter?
Pulmonx released its earnings results on Feb 21, 2024. The company reported -€0.338 earnings per share for the quarter, beating the consensus estimate of -€0.383 by €0.046.
Is Pulmonx overvalued?
According to Wall Street analysts Pulmonx’s price is currently Undervalued.
Does Pulmonx pay dividends?
Pulmonx does not currently pay dividends.
What is Pulmonx’s EPS estimate?
Pulmonx’s EPS estimate is -€0.44.
How many shares outstanding does Pulmonx have?
Currently, no data Available
What happened to Pulmonx’s price movement after its last earnings report?
Pulmonx reported an EPS of -€0.338 in its last earnings report, beating expectations of -€0.383. Following the earnings report the stock price went up 1.515%.
Which hedge fund is a major shareholder of Pulmonx?
Among the largest hedge funds holding Pulmonx’s share is PRIMECAP Management Co. It holds Pulmonx’s shares valued at 72M.
---
Pulmonx Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€15.78 (128.62% Upside)
€15.78 (128.62% Upside)
Blogger Sentiment
Bullish
DE:4NI Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth $128.1K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.19%
12-Months-Change
Fundamentals
Return on Equity
-44.68%
Trailing 12-Months
Asset Growth
-7.80%
Trailing 12-Months
Company Description
Pulmonx
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). the company's solutions comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the U.S. and international markets.
---
4NI Earnings Call
Q4 2024
0:00 / 0:00
---
4NI Stock 12 Months Forecast
Average Price Target
€15.78
▲(128.62% Upside)
Technical Analysis
Best Analysts Covering 4NI
1 Year
1 Year Success Rate
2/11 ratings generated profit
1 Year Average Return
-19.92%
reiterated a buy rating 2 months ago
Copying Joanne Wuensch's trades and holding each position for 1 Year would result in 18.18% of your transactions generating a profit, with an average return of -19.92% per trade.
---